BridgeBio Funding & Investors
BridgeBio Pharma, Inc. operates as a pharmaceutical company. The Company discovers and develops drugs for patients with grievous genetic diseases. BridgeBio Pharma offers medicines for different medical areas such as cardiology, neurology, oncology, and dermatology. BridgeBio Pharma serves patients in the State of California.
bridgebio.comTotal Amount Raised: $2,349,199,872
BridgeBio Funding Rounds
Post Ipo Equity
$250,000,000
Post Ipo Equity Investors
Qatar Investment AuthorityPost Ipo Debt
$250,000,000
Post Ipo Debt
$475,000,000
Series D
$299,200,000
Series D Investors
Cormorant CapitalViking Global InvestorsPerceptive AdvisorsKKRSequoia CapitalHercules CapitalAIG InvestmentsAisling CapitalSeries C
$135,000,000
Series C Investors
Cormorant CapitalViking Global InvestorsPerceptive AdvisorsKKRJanus FundAIG InvestmentsAisling CapitalPost Ipo Equity
$250,000,000
Post Ipo Equity Investors
Qatar Investment AuthoritySeries B
$33,100,000
Series B Investors
KKRSeries B
$6,900,000
Series B Investors
KKRPost Ipo Debt
$750,000,000
Post Ipo Equity
$150,000,000
Post Ipo Equity
$150,000,000
Funding info provided by Diffbot.